Preprint Review Version 6 This version is not peer-reviewed

Convalescent Plasma Therapy for Covid-19: State of the Art

Version 1 : Received: 6 April 2020 / Approved: 7 April 2020 / Online: 7 April 2020 (11:47:15 CEST)
Version 2 : Received: 8 April 2020 / Approved: 8 April 2020 / Online: 8 April 2020 (11:43:14 CEST)
Version 3 : Received: 11 April 2020 / Approved: 13 April 2020 / Online: 13 April 2020 (10:56:12 CEST)
Version 4 : Received: 20 April 2020 / Approved: 22 April 2020 / Online: 22 April 2020 (09:50:33 CEST)
Version 5 : Received: 27 April 2020 / Approved: 28 April 2020 / Online: 28 April 2020 (09:37:10 CEST)
Version 6 : Received: 27 May 2020 / Approved: 28 May 2020 / Online: 28 May 2020 (11:52:38 CEST)
Version 7 : Received: 1 July 2020 / Approved: 1 July 2020 / Online: 1 July 2020 (14:12:21 CEST)

How to cite: Focosi, D.; Tang, J.; Anderson, A.; Tuccori, M. Convalescent Plasma Therapy for Covid-19: State of the Art. Preprints 2020, 2020040097 (doi: 10.20944/preprints202004.0097.v6). Focosi, D.; Tang, J.; Anderson, A.; Tuccori, M. Convalescent Plasma Therapy for Covid-19: State of the Art. Preprints 2020, 2020040097 (doi: 10.20944/preprints202004.0097.v6).

Abstract

Convalescent blood product therapy has been introduced since early 1900s to treat emerging infectious disease based on the evidence that polyclonal neutralizing antibodies can reduce duration of viremia. Recent large outbreaks of viral diseases for whom effective antivirals or vaccines are still lacking has revamped the interest in convalescent plasma as life-saving treatments. This review summarizes historical settings of application, and surveys current technologies for collection, manufacturing, pathogen inactivation, and banking, with a focus on COVID-19.

Subject Areas

convalescent plasma; serology; pathogen reduction technologies; pathogen inactivation; COVID-19; SARS-CoV2

Comments (2)

Comment 1
Received: 28 May 2020
Commenter: Daniele Focosi
Commenter's Conflict of Interests: Author
Comment: Largely fixed after first round of peer-review (fixed syntax, reordered paragraphs), added trial results, added ongoing trials to Table 1. Added data for PRT efficacy for SARS-CoV2 and noninfectivity of SARS-CoV2 in peripheral blood.
+ Respond to this comment
Comment 2
Received: 31 May 2020
Commenter: David H. Muljono
The commenter has declared there is no conflict of interests.
Comment: This is a well-written manuscript reviewing CP treatment for COVID-19.
The authors describe their concern on TRALI, which can be life-threatening in donors receiving plasma transfusion for women who have been sensitized to fetal protein. This necessitates the screening for anti-HLA/HNA/HPA antibodies to prevent TRALI.
The European Commission mentions the need to test the three antibodies in the document '''An EU programme of COVID-19 convalescent plasma collection and transfusion", but not specifically refers to TRALI.

Anti-HLA and anti-HNA have been largely discussed with regard to their association with TRALI, However, anti-HPA is more related to purpura instead of TRALI in many publications. Could you add references regarding its relatedness with TRALI.

Thank you

David h. Muljono
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 2
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.